Cargando…

Retargeting T Cells for HER2-Positive Tumor Killing by a Bispecific Fv-Fc Antibody

To exploit the biological and pharmacological properties of immunoglobulin constant domain Fc fragment and increase the killing efficacy of T cells, a single chain variable fragment specific to CD3 was fused with Fcab (Fc antigen binding), a mutant Fc fragment with specificity against Human epiderma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Lei, He, Yanran, Zhang, Ge, Ma, Juan, Liu, Changzhen, He, Wen, Wang, Wei, Han, Huamin, Boruah, Bhargavi M., Gao, Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3781095/ https://www.ncbi.nlm.nih.gov/pubmed/24086580 http://dx.doi.org/10.1371/journal.pone.0075589

Ejemplares similares

High scFv-receptor affinity does not enhance the antitumor activity of HER2 retargeted measles virus
por: Suksanpaisan, Lukkana, et al.
Publicado: (2014)

Development of a Bispecific Antibody-Based Platform for Retargeting of Capsid Modified AAV Vectors
por: Kuklik, Juliane, et al.
Publicado: (2021)

A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3
por: Rau, Alexander, et al.
Publicado: (2021)

Vector design for enhancing expression level and assembly of knob-into-hole based FabscFv-Fc bispecific antibodies in CHO cells
por: Ong, Han Kee, et al.
Publicado: (2022)

Relative Contribution of Framework and CDR Regions in Antibody Variable Domains to Multimerisation of Fv- and scFv-Containing Bispecific Antibodies
por: Bhatta, Pallavi, et al.
Publicado: (2018)

Characterization and analysis of scFv-IgG bispecific antibody size variants
por: Cao, Mingyan, et al.
Publicado: (2018)

Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts
por: Aliperta, R, et al.
Publicado: (2015)

CXCL12 retargeting of an adenovirus vector to cancer cells using a bispecific adapter
por: Bhatia, Shilpa, et al.
Publicado: (2016)

Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release
por: Aschmoneit, Nadine, et al.
Publicado: (2021)

Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells
por: Grugan, Katharine D., et al.
Publicado: (2016)

Shortened Hinge Design of Fab x sdAb-Fc Bispecific Antibodies Enhances Redirected T-Cell Killing of Tumor Cells
por: Huang, Shuyu, et al.
Publicado: (2022)

Structural basis of a novel heterodimeric Fc for bispecific antibody production
por: Wei, Hudie, et al.
Publicado: (2017)

Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds
por: Liu, Hongyan, et al.
Publicado: (2017)

Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function
por: Escobar-Cabrera, Eric, et al.
Publicado: (2017)

A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy
por: Turini, Marc, et al.
Publicado: (2014)

Targeted Fcγ Receptor (FcγR)-mediated Clearance by a Biparatopic Bispecific Antibody
por: Kasturirangan, Srinath, et al.
Publicado: (2017)

A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells
por: Aschmoneit, Nadine, et al.
Publicado: (2021)

Characterization of a Novel Single-Chain Bispecific Antibody for Retargeting of T Cells to Tumor Cells via the TCR Co-Receptor CD8
por: Michalk, Irene, et al.
Publicado: (2014)

Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies
por: Zitron, Ian M, et al.
Publicado: (2013)

A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells
por: Li, Aifen, et al.
Publicado: (2016)

Single Domain Antibody Multimers Confer Protection against Rabies Infection
por: Boruah, Bhargavi M., et al.
Publicado: (2013)

CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer
por: Sun, Weilin, et al.
Publicado: (2022)

Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding
por: Davé, Emma, et al.
Publicado: (2016)

Targeting CEA in Pancreas Cancer Xenografts with a Mutated scFv-Fc Antibody Fragment
por: Girgis, Mark D, et al.
Publicado: (2011)

Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B
por: Rasetti-Escargueil, Christine, et al.
Publicado: (2015)

Preclinical Therapy of Disseminated HER-2(+) Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus
por: Nanni, Patrizia, et al.
Publicado: (2013)

Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors
por: Cheng, Ming, et al.
Publicado: (2016)

High-Throughput Generation of Bipod (Fab × scFv) Bispecific Antibodies Exploits Differential Chain Expression and Affinity Capture
por: Nesspor, Thomas C., et al.
Publicado: (2020)

Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody
por: Choi, Bryan D, et al.
Publicado: (2013)

Novel Human Bispecific Aptamer–Antibody Conjugates for Efficient Cancer Cell Killing
por: Passariello, Margherita, et al.
Publicado: (2019)

Understanding the structure–property relationship of bispecific monoclonal antibodies with Fc site-specific substitutions
por: Zhao, Bo, et al.
Publicado: (2023)

Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds
por: Malm, Magdalena, et al.
Publicado: (2016)

Bispecific Engineered Antibody Domains (Nanoantibodies) That Interact Noncompetitively with an HIV-1 Neutralizing Epitope and FcRn
por: Gong, Rui, et al.
Publicado: (2012)

Selection of bispecific antibodies with optimal developability using FcRn‑Ph‑HPLC as an optimized FcRn affinity chromatography method
por: Müller, Thomas, et al.
Publicado: (2023)

A systematic approach for analysis and characterization of mispairing in bispecific antibodies with asymmetric architecture
por: Wang, Chunlei, et al.
Publicado: (2018)

Biological Evaluation of (131)I- and CF750-Labeled Dmab(scFv)-Fc Antibodies for Xenograft Imaging of CD25-Positive Tumors
por: Fan, Qing, et al.
Publicado: (2014)

High-Level Production of scFv-Fc Antibody Using an Artificial Promoter System with Transcriptional Positive Feedback Loop of Transactivator in CHO Cells
por: Ying, Binbin, et al.
Publicado: (2023)

Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
por: Lopez-Albaitero, Andres, et al.
Publicado: (2017)

Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
por: Trinklein, Nathan D., et al.
Publicado: (2019)

Characterization of the single-chain Fv-Fc antibody MBP10 produced in Arabidopsis alg3 mutant seeds
por: Henquet, Maurice, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_vb3qifojng7sjb4bsq2stcrur7